Management of the elderly patient with gynecologic cancer: Report of the 2011 workshop in geriatric gynecologic oncology

International Journal of Gynecological Cancer

Volumn 22, Issue 1, 2012, Pages 161-169

  Suh, Dong Hoon ^a   Kang, Sokbom ^b   Lim, Myong Cheol ^b   Lee, Taek Sang ^c   Park, Jeong Yeol ^d   Kim, Tae Joong ^e   Kim, Jee Hyun ^f   Lee, Kwang Beom ^g   Park, Dong Choon ^h   Chung, Hyun Hoon ^a   Kim, Kidong ^f   Seo, Sang Soo ^b   Kim, Hak Jae ^a   Kim, Mi Kyung ^a   Ju, Woong ⁱ   Kim, Jae Weon ^a   Lichtman, Stuart M ^j   Park, Sang Yoon ^b  

^a Seoul National University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

^g Gachon University College of Medicine   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Ewha Womans University School of Medicine   (South Korea)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Diagnosis; Geriatric gynecologic oncology; Treatment

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; AGING; BLOOD TOXICITY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COGNITION; COMORBIDITY; CYTOREDUCTIVE SURGERY; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; ELDERLY CARE; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FAMILY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; GYNECOLOGIC CANCER; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUTRITION; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATIENT CARE; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SOCIAL SUPPORT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; UTERUS CANCER;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; GENITAL NEOPLASMS, FEMALE; GERIATRICS; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; PALLIATIVE CARE;

EID: 84863267772     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318234f8d5     Document Type: Review

References (87)

1. Quaglia A, Tavilla A, Shack L, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer. 2009;45:1006-1016.
2. Nelson NJ. Trial data lacking for elderly patients with breast cancer. J Natl Cancer Inst. 2000;92:1968-1969. (Pubitemid 32045887)
3. Freyer G, Tinker AV. Clinical trials and treatment of the elderly diagnosed with ovarian cancer. Int J Gynecol Cancer. 2011;21:776-781.
4. Harter P, du Bois A, Schade-Brittinger C, et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol. 2005;16:1801-1805. (Pubitemid 41631243)
5. Hamerman D. Toward an understanding of frailty. Ann Intern Med. 1999;130:945-950. (Pubitemid 29239594)
6. Freyer G, Lortholary A, Delcambre C, et al. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience. Clin Oncol (R Coll Radiol). 2004;16:17-23. (Pubitemid 38195865)
7. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824-1831. (Pubitemid 46860271)
8. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104:1998-2005. (Pubitemid 41513186)
9. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626-4631. (Pubitemid 41185131)
10. Saltzstein SL, Behling CA. 5- and 10-year survival in cancer patients aged 90 and older: a study of 37,318 patients from SEER. J Surg Oncol. 2002;81:113-116; discussion 7.
11. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, et al. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007;43:2161-2169. (Pubitemid 47539124)
12. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. J Clin Oncol. 2010;28:15s, (suppl; abstract 9001).
13. Hurria A. Geriatric assessment in oncology practice. J Am Geriatr Soc. 2009;57:S246-S249.
14. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241-252. (Pubitemid 41219694)
15. Overcash JA, Beckstead J, Extermann M, et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol. 2005;54:129-136. (Pubitemid 40544950)
16. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49: 1691-1699. (Pubitemid 34007998)
17. Schuurmans H, Steverink N, Lindenberg S, et al. Old or frail: what tells us more? J Gerontol A Biol Sci Med Sci. 2004;59:M962-M965.
18. Kellen E, Bulens P, Deckx L, et al. Identifying an accurate pre-screening tool in geriatric oncology. Crit Rev Oncol Hematol. 2010;75:243-248.
19. Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65:156-163.
20. Geisler JP, Geisler HE. Radical hysterectomy in the elderly female: a comparison to patients age 50 or younger. Gynecol Oncol. 2001;80:258-261. (Pubitemid 32158468)
21. Mousavi A, Karimi Zarchi M, Gilani MM, et al. Radical hysterectomy in the elderly. World J Surg Oncol. 2008;6:38.
22. Okuma K, Yamashita H, Kawana K, et al. Advanced age is a significant determinant of poor prognosis in patients treated with surgery plus postoperative radiotherapy for endometrial cancer. J Obstet Gynaecol Res. 2010;36:757-763.
23. Jolly S, Vargas CE, Kumar T, et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006;103:87-93. (Pubitemid 44374671)
24. Alektiar KM, Venkatraman E, Abu-Rustum N, et al. Is endometrial carcinoma intrinsically more aggressive in elderly patients? Cancer. 2003;98:2368-2377. (Pubitemid 37474159)
25. Truong PT, Kader HA, Lacy B, et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol. 2005;28:157-164.
26. Vaknin Z, Ben-Ami I, Schneider D, et al. A comparison of perioperative morbidity, perioperative mortality, and disease-specific survival in elderly women (>or = 70 years) versus younger women (<70 years) with endometrioid endometrial cancer. Int J Gynecol Cancer. 2009;19: 879-883.
27. Ahmed A, Zamba G, DeGeest K, et al. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992-2002. Gynecol Oncol. 2008;111:35-40.
28. Fleming ND, Lentz SE, Cass I, et al. Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma? Gynecol Oncol. 2011;120:189-192.
29. Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627. (Pubitemid 47372600)
30. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71:606-614.
31. Gardner GJ. Ovarian cancer cytoreductive surgery in the elderly. Curr Treat Options Oncol. 2009;10:171-179.
32. Bruchim I, Altaras M, Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol. 2002;86:274-278. (Pubitemid 35425522)
33. Cloven NG, Manetta A, Berman ML, et al. Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol. 1999;73:137-139. (Pubitemid 29177613)
34. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99:352-357. (Pubitemid 41502843)
35. Fotopoulou C, Savvatis K, Steinhagen-Thiessen E, et al. Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival. Int J Gynecol Cancer. 2010;20:34-40.
36. Janda M, Youlden DR, Baade PD, et al. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer. 2008;18:896-907.
37. Lim MC, Kang S, Song YJ, et al. Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer. J Korean Med Sci. 2010;25:1034-1040.
38. Maas HA, Kruitwagen RF, Lemmens VE, et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97:104-109. (Pubitemid 40403681)
39. Marchetti DL, Lele SB, Priore RL, et al. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol. 1993;49:86-91. (Pubitemid 23148588)
40. Markman M, Lewis JL Jr, Saigo P, et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1993;71:634-637. (Pubitemid 23021262)
41. McLean KA, Shah CA, Thompson SA, et al. Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol. 2010;118:43-46.
42. Moore KN, Reid MS, Fong DN, et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008;110:133-139.
43. Petignat P, Fioretta G, Verkooijen HM, et al. Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol. 2004;13:181-186. (Pubitemid 40029613)
44. Pignata S, Ferrandina G, Scarfone G, et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol. 2009;71:233-241.
45. Renaud MC, Plante M, Gregoire J, et al. Ovarian cancer in the elderly patient: are we doing enough? J Obstet Gynaecol Can. 2010;32:1049-1055.
46. Sharma S, Driscoll D, Odunsi K, et al. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193:2077-2082. (Pubitemid 41737638)
47. Susini T, Amunni G, Busi E, et al. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer. 2007;17:581-588. (Pubitemid 46744001)
48. Uyar D, Frasure HE, Markman M, et al. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98:403-408. (Pubitemid 41169151)
49. Wright JD, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol. 2004;190:1398-1400. (Pubitemid 38692227)
50. Wimberger P, Lehmann N, Kimmig R, et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft. Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2006;100:300-307. (Pubitemid 43075262)
51. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259. (Pubitemid 34177431)
52. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77-85.
53. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 2001;82:435-441. (Pubitemid 32826441)
54. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103: 1083-1090. (Pubitemid 44821338)
55. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650-654. (Pubitemid 39194456)
56. Gershenson DM, Mitchell MF, Atkinson N, et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer. 1993;71:638-643. (Pubitemid 23021263)
57. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
58. Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010;16:CD007822.
59. Park JY, Eom JM, Kim DY, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2010;101:418-424.
60. Bae J, Lim MC, Choi JH, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009;20:101-106.
61. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-1939. (Pubitemid 43673208)
62. Wright J, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197-1203. (Pubitemid 351481683)
63. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part IVmalignancies of the cervix, ovary, vagina and vulva. Cancer. 2004;101:671-681. (Pubitemid 39030921)
64. Ikushima H, Takegawa Y, Osaki K, et al. Radiation therapy for cervical cancer in the elderly. Gynecol Oncol. 2007;107:339-343. (Pubitemid 47575738)
65. Kunos C, Tian C, Waggoner S, et al. Retrospective analysis of concomitant cisplatin during radiation in patients aged55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study. Int J Gynecol Cancer. 2009;19:1258-1263.
66. Ikushima H, Osaki K, Furutani S, et al. Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiat Med. 2006;24:115-121.
67. 2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: a randomized controlled trial. Asian Pac J Cancer Prev. 2010;11:201-207.
68. Pignon T, Gregor A, Schaake Koning C, et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol. 1998;46:239-248. (Pubitemid 28157273)
69. Pignon T, Horiot JC, Bolla M, et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42:107-120. (Pubitemid 27132740)
70. Pignon T, Horiot JC, Van den Bogaert W, et al. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer. 1996;32A:2075-2081. (Pubitemid 26419456)
71. Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29:1692-1700.
72. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816-823.
73. Moore KN, Frank SG, Alward EK, et al. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009;115:1472-1480.
74. Hilpert F, du Bois A, Greimel ER, et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or = 70 years with advanced ovarian cancer-a study by the AGO OVAR Germany. Ann Oncol. 2007;18:282-287. (Pubitemid 46323094)
75. Eisenhauer EL, Tew WP, Levine DA, et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106:381-387. (Pubitemid 47087938)
76. Tredan O, Geay JF, Touzet S, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol. 2007;18:256-262. (Pubitemid 46323090)
77. Fader AN, von Gruenigen V, Gibbons H, et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33-38.
78. Kothari R, Nagel C, Koopmeiners JS, et al. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol. 2010;119:491-495.
79. Matulonis UA, Krag KJ, Krasner CN, et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol. 2009;112:394-399.
80. Pignata S, Breda E, Scambia G, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66:229-236.
81. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795-1800. (Pubitemid 41631242)
82. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
83. Tew WP, Java J, Chi D, et al. Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182). J Clin Oncol. 2010;28:15s, (suppl; abstract 5030).
84. Kurtz JE, Kaminsky MC, Floquet A, et al. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. [published online ahead of print March 14, 2011]. Ann Oncol. doi:10.1093/annonc/mdr001.
85. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol. 2011;29:333s. (suppl; abstract LBA5007).
86. Wagnerova M. Geriatric patients with advanced cancer. In: Catane R, Cherny N, Kloke M, et al, eds. Handbook of Advanced Cancer Care. 1st ed. United Kingdom: Taylor & Francis; 2006:204-212.
87. Khatcheressian JL,Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24:5091-5097. (Pubitemid 46631413)